Within-individual study designs resolve GLP-1 psychiatric safety divergence by eliminating confounding by indication that creates spurious risk signals in matched cohort studies
The 195% MDD risk increase in matched cohorts reflects selection bias—people prescribed GLP-1s have worse baseline mental health—while within-individual comparison shows protective effects
Claim
The apparent divergence in GLP-1 psychiatric safety evidence—matched cohort studies showing 195% increased MDD risk versus RCTs and within-individual studies showing protective or neutral effects—is resolved by understanding confounding by indication. The Swedish Lancet Psychiatry study (March 2026) used within-individual stratified Cox models comparing the same person's psychiatric outcomes during periods ON versus OFF semaglutide. This design eliminates all time-invariant confounding including baseline psychiatric severity, unmeasured comorbidities, and social circumstances that propensity score matching cannot fully capture. The finding of 42% reduced psychiatric worsening during semaglutide use periods directly contradicts the matched cohort signal and demonstrates that the 195% MDD risk increase reflects selection bias: people prescribed GLP-1s for obesity have systematically worse baseline mental health than matched controls, even after propensity score adjustment. The FDA meta-analysis of 91 placebo-controlled RCTs (107,910 patients) showing no increased psychiatric risk converges with the within-individual finding, while matched cohort studies diverge due to residual confounding. This establishes a methodological hierarchy: within-individual designs and RCTs should dominate inference over matched cohort studies when confounding by indication is structurally present. The resolution has major implications for GLP-1 prescribing guidelines and psychiatric screening protocols.
Sources
1- 2026 03 lancetpsychiatry glp1 mental illness swedish cohort
inbox/queue/2026-03-lancetpsychiatry-glp1-mental-illness-swedish-cohort.md
Reviews
1## Criterion-by-Criterion Review **1. Schema:** All five files are type:claim with complete frontmatter including type, domain, confidence, source, created, and description fields—schema is valid for claim content type. **2. Duplicate/redundancy:** The three enrichments to existing claims add the Swedish study as converging evidence without duplicating the existing evidence structure; the two new claims address distinct aspects (within-individual psychiatric effects vs. methodological resolution of confounding) that are not redundant with each other or existing claims. **3. Confidence:** Both new claims are marked "likely" which is appropriate given the large sample size (n=95,490), within-individual design strength, and convergence with FDA RCT meta-analysis, though the effect sizes (40-50% reductions) are notably large for psychiatric outcomes. **4. Wiki links:** Multiple wiki links reference claims like [[glp1-eating-disorder-risk-doubles-with-prior-mental-health-history]] and [[glp1-eating-disorder-causality-expert-divergence-reflects-evidence-gap]] that may not exist in the current branch, but broken links are expected in collaborative knowledge bases and do not affect approval. **5. Source quality:** The Lancet Psychiatry source from Karolinska Institutet with Swedish national registry data (n=95,490) is highly credible for psychiatric epidemiology claims, and the within-individual design methodology is appropriately characterized as superior to matched cohort approaches for addressing confounding by indication. **6. Specificity:** Both new claims are falsifiable—one could find that within-individual designs show no protective effect or that the 40-50% reduction estimates are artifacts of unmeasured time-varying confounding; the methodological claim about confounding by indication could be challenged by demonstrating adequate propensity score matching eliminates the divergence. <!-- VERDICT:LEO:APPROVE -->
Connections
7Related 6
- glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap
- glp1-eating-disorder-causality-expert-divergence-reflects-evidence-gap
- glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations
- semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism
- glp1-eating-disorder-risk-doubles-with-prior-mental-health-history
- glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific